PolyBio Announces Inaugural Convergence Summit on Pathogen Persistence Across Chronic Disease and Aging

ملخص مفصل
The November 18–20 meeting at the American Academy of Arts and Sciences will bring together researchers, clinicians, industry leaders, and patients to discuss advances in…
The November 18–20 meeting at the American Academy of Arts and Sciences will bring together researchers, clinicians, industry leaders, and patients to discuss advances in diagnostics and treatments for infection-associated chronic illnesses
MEDFORD, Mass., Nov. 16, 2026 /PRNewswire/ -- PolyBio Research Foundation today announced the inaugural PolyBio Convergence Summit, taking place November 18–20 at the American Academy of Arts and Sciences in Cambridge, Massachusetts. The three-day meeting will examine pathogen persistence, in which viruses, bacteria, parasites, or other pathogens remain in the body or brain after the initial infection. Speakers will explore how this ongoing activity can contribute to chronic disease and aging.
The Summit builds on PolyBio's global research consortium, which connects investigators across more than 25 academic institutions. In recent years, PolyBio has expanded its network to include diagnostic developers, biotechnology and pharmaceutical leaders, commercialization experts, clinical trialists, medical educators, regulatory leaders, and investors. The program will explore persistent infection in Long COVID, chronic tick-borne illnesses, neurodegenerative diseases, and autoimmune conditions, as well as its potential role in aging.
"PolyBio has spent years building a global network of leading researchers and innovators across academia, diagnostics, biotechnology, and clinical care. At our inaugural Convergence Summit, we're bringing these communities together with the people who can turn scientific discoveries into real-world solutions for patients," said Amy Proal, PhD, CEO of PolyBio Research Foundation and Summit Chair. "A scientist developing a way to detect persistent infection can sit down with the people who can validate the test, use it to design a clinical trial, and help bring it into care. That's the kind of conversation we built this Summit for.
The Summit will take place at the House of the Academy, the Cambridge…
PolyBio…
مطلع المقال، مقتطف من PR Newswire. لقراءة المقال كاملًا، افتحه على موقع الناشر.
يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.prnewswire.com)